BACKGROUND: Treatment with HMG-CoA reductase inhibitors (statins) reduces the morbidity and mortality of coronary artery disease (CAD). In addition to their lipid-lowering actions, pleiotropic effects of statins have been demonstrated. OBJECTIVE: The aim of the present study was to assess if atorvastatin therapy has an impact on haemostasis, fibrinolysis and inflammation in normocholesterolaemic patients with CAD. METHODS:Fifty-four patients with CAD who had receivedatorvastatin treatment for at least 8 weeks (mean dosage 30 mg/day) and 54 patients with CAD who had not receivedatorvastatin therapy were selected from a larger prospective, randomized, double-blind study for inclusion in this post hoc analysis. Patients were matched by their total cholesterol levels. All patients were normocholesterolaemic. RESULTS: In the atorvastatin-treated patients significantly lower plasma levels of thrombin-antithrombin complexes (p < 0.05), plasminogen activator inhibitor-1 activity (PAI-1) [p < 0.05], soluble vascular cell adhesion molecule-1 (p < 0.05), soluble platelet selectin (p < 0.05) and high-sensitivity C-reactive protein (p < 0.05) were measured compared with patients not on atorvastatin therapy. Additionally, a strong trend towards lower soluble intercellular adhesion molecule-1 plasma levels was detected in patients treated with atorvastatin. No differences were found in tissue-type plasminogen activator antigen, plasmin-plasmin inhibitor complexes, fibrinogen, D-dimer and activated factor XII values. CONCLUSION:Atorvastatin appears to have an effect on coagulation activation, fibrinolysis and inflammation in patients with CAD. Reduction in PAI-1 and reduced thrombin formation may have an impact on cardiovascular morbidity and mortality in patients with CAD.
RCT Entities:
BACKGROUND: Treatment with HMG-CoA reductase inhibitors (statins) reduces the morbidity and mortality of coronary artery disease (CAD). In addition to their lipid-lowering actions, pleiotropic effects of statins have been demonstrated. OBJECTIVE: The aim of the present study was to assess if atorvastatin therapy has an impact on haemostasis, fibrinolysis and inflammation in normocholesterolaemic patients with CAD. METHODS: Fifty-four patients with CAD who had received atorvastatin treatment for at least 8 weeks (mean dosage 30 mg/day) and 54 patients with CAD who had not received atorvastatin therapy were selected from a larger prospective, randomized, double-blind study for inclusion in this post hoc analysis. Patients were matched by their total cholesterol levels. All patients were normocholesterolaemic. RESULTS: In the atorvastatin-treated patients significantly lower plasma levels of thrombin-antithrombin complexes (p < 0.05), plasminogen activator inhibitor-1 activity (PAI-1) [p < 0.05], soluble vascular cell adhesion molecule-1 (p < 0.05), soluble platelet selectin (p < 0.05) and high-sensitivity C-reactive protein (p < 0.05) were measured compared with patients not on atorvastatin therapy. Additionally, a strong trend towards lower soluble intercellular adhesion molecule-1 plasma levels was detected in patients treated with atorvastatin. No differences were found in tissue-type plasminogen activator antigen, plasmin-plasmin inhibitor complexes, fibrinogen, D-dimer and activated factor XII values. CONCLUSION:Atorvastatin appears to have an effect on coagulation activation, fibrinolysis and inflammation in patients with CAD. Reduction in PAI-1 and reduced thrombin formation may have an impact on cardiovascular morbidity and mortality in patients with CAD.
Authors: L Puccetti; A L Pasqui; M Pastorelli; G Bova; M Cercignani; A Palazzuoli; P Angori; A Auteri; F Bruni Journal: Eur J Clin Invest Date: 2002-12 Impact factor: 4.686
Authors: M W Mosesson; K R Siebenlist; I Hernandez; K N Lee; V J Christiansen; P A McKee Journal: J Thromb Haemost Date: 2008-06-16 Impact factor: 5.824
Authors: F Bruni; A L Pasqui; M Pastorelli; G Bova; M Di Renzo; M Cercigani; A Leo; A Auteri; L Puccetti Journal: Int J Cardiol Date: 2004-06 Impact factor: 4.164
Authors: Luis Miguel Blanco-Colio; Jose Luis Martín-Ventura; Eduardo de Teresa; Csaba Farsang; Allan Gaw; GianFranco Gensini; Lawrence A Leiter; Anatoly Langer; Pierre Martineau; Jesús Egido Journal: Am Heart J Date: 2007-05 Impact factor: 4.749
Authors: T Murakami; Y Komiyama; M Masuda; M Karakawa; T Iwasaka; H Takahashi Journal: Arterioscler Thromb Vasc Biol Date: 1995-08 Impact factor: 8.311
Authors: Hannes Franz Alber; Matthias Frick; Alois Süssenbacher; Jakob Dörler; Wolfgang Dichtl; Eva-Maria Stocker; Otmar Pachinger; Franz Weidinger Journal: Wien Med Wochenschr Date: 2007-02
Authors: Suzanne Schol-Gelok; Tom van der Hulle; Joseph S Biedermann; Teun van Gelder; Frederikus A Klok; Liselotte M van der Pol; Jorie Versmissen; Menno V Huisman; Marieke J H A Kruip Journal: Eur J Clin Invest Date: 2018-05-13 Impact factor: 4.686
Authors: N B Adams; P L Lutsey; A R Folsom; D H Herrington; C T Sibley; N A Zakai; S Ades; G L Burke; M Cushman Journal: J Thromb Haemost Date: 2013-06 Impact factor: 5.824